Please login to the form below

Not currently logged in
Email:
Password:

liver transplant

This page shows the latest liver transplant news and features for those working in and with pharma, biotech and healthcare.

Zydus Cadila scores first ever NASH approval, in India

Zydus Cadila scores first ever NASH approval, in India

NASH is characterised by a build-up of fat that can lead to fibrosis, cirrhosis and sometimes the need for a liver transplant, in severe cases. ... The drug met both primary and secondary endpoints, demonstrating a significant reduction in liver fat,

Latest news

  • Alnylam scores EU approval for RNAi drug Givlaari Alnylam scores EU approval for RNAi drug Givlaari

    Hepatic porphyrias occur due to a deficiency in the liver and are associated with painful attacks that often require hospitalisation and treatment with intravenous hemin therapy. ... Sometimes, the disease can lead to patients requiring a liver transplant

  • Boehringer bolsters NASH pipeline with Enleofen link-up Boehringer bolsters NASH pipeline with Enleofen link-up

    Inhibiting IL-11 has been shown in preclinical studies to prevent and reverse inflammation and fibrosis as well as restore function in a range of organs, including liver, lung, kidney, retina, ... It is characterised by a build-up of fat that can lead to

  • Northsea Therapeutics raises $40m to develop fish oil NASH drug Northsea Therapeutics raises $40m to develop fish oil NASH drug

    Northsea will also use the money raised to develop two other omega 3 candidats for use in dyslipidaemia and parenteral nutrition associated liver disease. ... The disease causes fatty build-up and fibrosis in the liver and in serious cases leads to

  • CymaBay Therapeutics plummets after abandoning NASH drug CymaBay Therapeutics plummets after abandoning NASH drug

    Failure of mid-stage liver disease candidate caused shares to slip over 75%. ... NASH is characterised by a build-up of fat that can lead to fibrosis, cirrhosis and in some cases the need for a liver transplant.

  • FDA clears Alnylam’s second RNAi drug for rare disease FDA clears Alnylam’s second RNAi drug for rare disease

    Hepatic porphyrias are those in which the deficiency occurs in the liver and – along with painful attacks that often require hospitalisation and treatment with intravenous hemin therapy – can sometimes lead to ... patients requiring a liver transplant

More from news
Approximately 3 fully matching, plus 46 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...